Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus. The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides […]
Boehringer Ingelheim Pharmaceuticals
More Respimat data from Boehringer
Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo. The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London. This comes 1 day after results from another clinical trial […]
Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath. When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along […]
Boehringer Ingelheim, Qualcomm team on connected inhaler
Boehringer Ingelheim Pharmaceuticals and Qualcomm (NSDQ:QCOM) subsidiary Qualcomm Life yesterday said they’re partnering to create an inhaler that can track user information, hoping to improve outcomes for chronic obstructive pulmonary disease. Boehringer tapped Qualcomm to create a low-power, disposable module for Boehringer’s Respimat inhaler, using Qualcomm’s 2net Design platform to build a wireless communication component into the inhaler. The […]
